Elicio Therapeutics (ELTX) Misses Q3 EPS by 60c Nov 13, 2025 06:49PM
Elicio Therapeutics (ELTX) PT Raised to $13 at H.C. Wainwright Jul 17, 2025 06:44AM
Elicio Therapeutics (ELTX) Secures $10 Million in Financing Jun 4, 2025 08:00AM
Elicio Therapeutics (ELTX) Appoints Preetam Shah as Chief Strategy and Financial Officer Mar 24, 2025 07:00AM
Elicio Therapeutics (ELTX) Announces 1.26M Share Offering at $7.925/sh Jan 30, 2025 08:00AM


Jan 22, 2025 07:30AM Elicio Therapeutics (ELTX) Reaches Alignment with FDA on ELI-002 Registrational Strategy
Dec 12, 2024 07:00AM Elicio Therapeutics (ELTX) Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study
Dec 3, 2024 07:01AM Elicio Therapeutics (ELTX) Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
Nov 13, 2024 04:25PM Elicio Therapeutics (ELTX) Files for 3.44M Share Offering by Selling Stockholders
Nov 7, 2024 04:08PM Elicio Therapeutics (ELTX) Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study
Oct 30, 2024 04:13PM Jones Trading Starts Elicio Therapeutics (ELTX) at Buy
Jun 28, 2024 09:01AM Elicio Therapeutics (ELTX) Prices $11.5M Offering at $5/sh
Jun 27, 2024 04:05PM Elicio Therapeutics (ELTX) Announces Proposed Share Offering
Jun 27, 2024 04:01PM Elicio Therapeutics (ELTX) Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P